Literature DB >> 8394200

Expression of carbohydrate antigens in human pulmonary adenocarcinoma.

T Kawai1, M Suzuki, K Kase, Y Ozeki.   

Abstract

BACKGROUND: The altered and anomalous expression of carbohydrate antigens (CA) occur in patients with lung carcinomas.
METHODS: To investigate the relationship between prognosis and immunohistochemical findings of CA in serum and pulmonary adenocarcinomas (PA), PA specimens surgically resected from 102 patients were studied with the use of A, B, H, Lewis(Le)a, Le(b), Le(x), Le(y), sialyl Le(a) (FH-7), sialyl Le(x-i) (SLX) (FH-6), sialosyl Tn (TKH-2), and CA 19-9. The Lewis blood group types were determined by the dot blotting method on patients' serum using monoclonal anti-Le(a), Le(b), Le(x), and Le(y). Formalin-fixed paraffin-embedded PA sections were stained using the avidin-biotin-peroxidase complex methods.
RESULTS: There was no correlation between the patients' postoperative survival and tissue expression of CA, although survival correlated with the clinical stages, histologic differentiation of PA, and serum SLX in Stage 4. The higher the positive rate of both Le(b) and Le(y), the better their differentiation in PA specimens. Regardless of blood group type, PA showed high positive reactions for FH-6 (88%) and Le(y) (87%). The serum concentration of CA 19-9 correlated with immunohistochemical reactions of tumors (Spearman correlation coefficient = 0.33, P = 0.02). The expression of Le(a) in Lewis (a-b+) phenotype patients and Type 2 CA, such as Le(y) and FH-6, is characteristic in PA.
CONCLUSIONS: The findings suggest that CA tissue expression may not reflect postoperative survival length of patients with PA, but biological aberrant fucosylation or sialylation as well as morphologic alteration may occur in neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394200     DOI: 10.1002/1097-0142(19930901)72:5<1581::aid-cncr2820720515>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Identification and characterization of different subpopulations in a human lung adenocarcinoma cell line (A549).

Authors:  M V Croce; A G Colussi; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 3.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

4.  Cell type-dependent alterations of binding of synthetic blood group antigen-related oligosaccharides in lung cancer.

Authors:  K Kayser; N V Bovin; T V Zemlyanukhina; S Donaldo-Jacinto; J Koopmann; H J Gabius
Journal:  Glycoconj J       Date:  1994-08       Impact factor: 2.916

5.  Immunohistopathological characterizatin of spontaneous metastases in a human lung mucoepidermoid adenocarcinoma (HLMC) xenograft.

Authors:  M V Croce; A G Colussi; M G De Bravo; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 6.  Glycosylation Changes in Brain Cancer.

Authors:  Lucas Veillon; Christina Fakih; Hadi Abou-El-Hassan; Firas Kobeissy; Yehia Mechref
Journal:  ACS Chem Neurosci       Date:  2017-11-07       Impact factor: 4.418

7.  Relation between the serum E-selectin level and the survival rate of patients with resected non-small cell lung cancers.

Authors:  G Tsumatori; Y Ozeki; K Takagi; T Ogata; S Tanaka
Journal:  Jpn J Cancer Res       Date:  1999-03

8.  High TSTA3 Expression as a Candidate Biomarker for Poor Prognosis of Patients With ESCC.

Authors:  Jie Yang; Pengzhou Kong; Jian Yang; Zhiwu Jia; Xiaoling Hu; Zianyi Wang; Heyang Cui; Yanghui Bi; Yu Qian; Hongyi Li; Fang Wang; Bin Yang; Ting Yan; Yanchun Ma; Ling Zhang; Caixia Cheng; Bin Song; Yaoping Li; Enwei Xu; Haiyan Liu; Wei Gao; Juan Wang; Yiqian Liu; Yuanfang Zhai; Lu Chang; Yi Wang; Yingchun Zhang; Ruyi Shi; Jing Liu; Qi Wang; Xiaolong Cheng; Yongping Cui
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

9.  The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types.

Authors:  Haiqing Chen; Fangqiu Fu; Yue Zhao; Haoxuan Wu; Hong Hu; Yihua Sun; Yawei Zhang; Jiaqing Xiang; Yang Zhang
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.